Orthofix has announced the full market release and first implants of Legacy Demineralised Bone Matrix (DBM), a putty for filling voids or gaps in bony defects or traumatic injuries of the spine, pelvis or extremities.
Alan Daniels, chief of spine surgery at University Orthopedics (Providence, USA) said: “Bone healing is a dynamic process where multiple factors play an integral role in deciding which biologic best meets the individual needs of the patient to aid them on their road to recovery. Legacy DBM provides a cost-effective option, without compromising clinical experience or the handling needed in a bone matrix.”
Legacy DBM, which is processed by MTF Biologics, has a puttylike consistency which, according to the company, features desirable handling and can be used as an extender with autograft or allograft or with bone marrow aspirate.
Orthofix’s president of global spine, Kevin Kenny, added: “The Legacy DBM is another example of our continued commitment to expand biologic offerings to meet the needs of surgeons and their patients.
“In the past year alone, we have introduced five new biologics including the Virtuos lyograft, a first-of-its-kind, shelf-stable, and complete autograft substitute. In addition, we recently announced a partnership with CGBio, a developer of innovative bone grafts, representing the first step in bringing Novosis—the next evolution in bone growth factor technology—to the US and Canadian markets.
“We understand there are unique surgeon users for a wide range of bone-grafting options, and it is our goal to be a leading provider of these biologic offerings to our customers.”